BlackRock’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$341M Buy
18,994,958
+4,239,681
+29% +$80.2M 0.01% 1476
2026
Q1
$321M Buy
14,755,277
+472,024
+3% +$9.14M 0.01% 1399
2025
Q4
$307M Buy
14,283,253
+1,083,408
+8% +$22.8M 0.01% 1413
2025
Q3
$254M Buy
13,199,845
+1,084,623
+9% +$19.3M ﹤0.01% 1521
2025
Q2
$207M Buy
12,115,222
+2,208,354
+22% +$94.2M ﹤0.01% 1608
2025
Q1
$632M Sell
9,906,868
-1,285,118
-11% -$135M 0.01% 878
2024
Q4
$1.36B Buy
11,191,986
+168,672
+2% +$20.7M 0.03% 518
2024
Q3
$1.38B Buy
11,023,314
+698,910
+7% +$96.6M 0.03% 505
2024
Q2
$1.63B Buy
10,324,404
+4,364,034
+73% +$561M 0.04% 414
2024
Q1
$772M Sell
5,960,370
-251,422
-4% -$30.8M 0.02% 745
2023
Q4
$599M Buy
6,211,792
+178,057
+3% +$17.1M 0.02% 870
2023
Q3
$731M Buy
6,033,735
+530,269
+10% +$59.9M 0.02% 678
2023
Q2
$630M Buy
5,503,466
+220,771
+4% +$28.5M 0.02% 785
2023
Q1
$728M Sell
5,282,695
-199,471
-4% -$25.9M 0.02% 678
2022
Q4
$710M Buy
5,482,166
+144,862
+3% +$16.8M 0.02% 677
2022
Q3
$590M Sell
5,337,304
-270,359
-5% -$27.3M 0.02% 729
2022
Q2
$420M Buy
5,607,663
+60,704
+1% +$4.47M 0.01% 970
2022
Q1
$433M Buy
5,546,959
+261,725
+5% +$20M 0.01% 1088
2021
Q4
$476M Buy
5,285,234
+525,016
+11% +$44.9M 0.01% 1068
2021
Q3
$440M Sell
4,760,218
-106,133
-2% -$8.18M 0.01% 1084
2021
Q2
$378M Sell
4,866,351
-647,199
-12% -$49.1M 0.01% 1263
2021
Q1
$411M Buy
5,513,550
+134,335
+2% +$12.4M 0.01% 1182
2020
Q4
$917M Sell
5,379,215
-76,376
-1% -$11.3M 0.03% 565
2020
Q3
$766M Buy
5,455,591
+83,856
+2% +$12.7M 0.03% 565
2020
Q2
$861M Buy
5,371,735
+484,291
+10% +$65.9M 0.03% 476
2020
Q1
$478M Buy
4,887,444
+247,159
+5% +$28.3M 0.02% 627
2019
Q4
$599M Buy
4,640,285
+134,544
+3% +$13.6M 0.02% 693
2019
Q3
$339M Buy
4,505,741
+583,198
+15% +$68.9M 0.01% 1027
2019
Q2
$596M Sell
3,922,543
-264,721
-6% -$32.2M 0.03% 655
2019
Q1
$499M Sell
4,187,264
-657,967
-14% -$84.6M 0.02% 733
2018
Q4
$529M Buy
4,845,231
+36,972
+0.8% +$4.62M 0.03% 621
2018
Q3
$777M Buy
4,808,259
+121,003
+3% +$16.5M 0.03% 519
2018
Q2
$620M Sell
4,687,256
-1,374,153
-23% -$130M 0.03% 600
2018
Q1
$449M Sell
6,061,409
-224,934
-4% -$15M 0.02% 772
2017
Q4
$350M Buy
6,286,343
+58,433
+0.9% +$3.1M 0.02% 951
2017
Q3
$282M Buy
6,227,910
+1,008,468
+19% +$40.3M 0.01% 1074
2017
Q2
$176M Sell
5,219,442
-73,287
-1% -$2.39M 0.01% 1408
2017
Q1
$157M Buy
5,292,729
+5,175,193
+4,403% +$160M 0.01% 1468
2016
Q4
$3.22M Buy
117,536
+8,256
+8% +$332K ﹤0.01% 1060
2016
Q3
$6.71M Buy
109,280
+91,084
+501% +$2.75M 0.01% 846
2016
Q2
$347K Buy
18,196
+15,160
+499% +$281K ﹤0.01% 1824
2016
Q1
$60K Buy
3,036
+1,673
+123% +$29.2K ﹤0.01% 2273
2015
Q4
$53K Sell
1,363
-27,370
-95% -$887K ﹤0.01% 2018
2015
Q3
$923K Buy
28,733
+27,649
+2,551% +$938K ﹤0.01% 1316
2015
Q2
$33K Sell
1,084
-112
-9% -$2.29K ﹤0.01% 2164
2015
Q1
$16K Hold
1,196
﹤0.01% 2470
2014
Q4
$17K Hold
1,196
﹤0.01% 2455
2014
Q3
$25K Hold
1,196
﹤0.01% 2230
2014
Q2
$36K Sell
1,196
-2
-0.2% -$63 ﹤0.01% 2084
2014
Q1
$29K Buy
1,198
+64
+6% +$1.63K ﹤0.01% 2176
2013
Q4
$23K Buy
1,134
+96
+9% +$2.85K ﹤0.01% 2298
2013
Q3
$49K Hold
1,038
﹤0.01% 1849
2013
Q2
$40K Buy
+1,038
New +$37.1K ﹤0.01% 1954

Other funds holding SRPT

BlackRock's SRPT Position: Q2 2026 in Review

BlackRock increased its Sarepta Therapeutics (SRPT) stake by 29% in Q2 2026, buying an estimated $80.2M and bringing the position to 18,994,958 shares worth $341M. The position accounts for 0.01% of the portfolio, ranked #1476.

BlackRock first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.63B in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • BlackRock held 18,994,958 shares of Sarepta Therapeutics worth $341M as of Q2 2026.
  • BlackRock bought 4,239,681 Sarepta Therapeutics shares in Q2 2026, an estimated $80.2M.
  • Sarepta Therapeutics made up 0.01% of BlackRock's portfolio in Q2 2026, its #1476 holding.
  • BlackRock first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's Sarepta Therapeutics position peaked at $1.63B in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.